Literature DB >> 9620168

Purification of guinea pig YKL40 and modulation of its secretion by cultured articular chondrocytes.

F De Ceuninck1, P Pastoureau, F Bouet, J Bonnet, P M Vanhoutte.   

Abstract

The aim of this study was to purify, characterize, and study the regulation at the chondrocyte level of the guinea pig (gp) homologue of human (R) YKL40, a putative marker of arthritic disorders. Studying YKL40 in guinea pigs is of particular interest, as age-related osteoarthritis develops in this species spontaneously. Both N-terminal sequencing and total amino acid composition of gpYKL40 purified from the secretion medium of cultured articular chondrocytes indicate a high degree of identity with hYKL40. gpYKL40 was found to contain complex N-linked carbohydrate, as demonstrated by N-glycosidase F and endoglycosidase F digestion. Isoelectric focusing demonstrated the presence of a major band at pI 6.7. The secretion of gpYKL40 by confluent articular chondrocytes in the extracellular medium was studied by immunoblotting. gpYKL40 was released by chondrocytes continuously over a 7 day period and did not appear to be degraded by proteinases, as its signal intensity in cell-free medium at 37 degrees C did not decrease with time. Thus, gpYKL40 displays high stability and accumulates in extracellular medium without reaching a steady-state level. Among the main factors known to regulate cartilage metabolism, IL-1beta, TNF-alpha, bFGF, or 1,25(OH)2D3 did not alter the basal level of gpYKL40, and retinoic acid had a slight inhibitory effect; TGF-beta and IGF-I and -II dose-dependently and inversely modulated this basal level. TGF-beta at 5 ng/ml decreased extracellular gpYKL40 2.9-fold, whereas IGF-I and IGF-II at 50 ng/ml increased extracellular gpYKL40 3.6- and 3.4-fold, respectively. The present biochemical and biological findings give new insights for studying the function of YKL40 in cartilage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620168     DOI: 10.1002/(sici)1097-4644(19980615)69:4<414::aid-jcb3>3.0.co;2-q

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  Inhibition of Mammalian Glycoprotein YKL-40: IDENTIFICATION OF THE PHYSIOLOGICAL LIGAND.

Authors:  Abhishek A Kognole; Christina M Payne
Journal:  J Biol Chem       Date:  2017-01-04       Impact factor: 5.157

Review 2.  The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.

Authors:  Changbin Zhu; Johan M Kros; Caroline Cheng; Dana Mustafa
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

Review 3.  Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells.

Authors:  Katrin Eurich; Mayuko Segawa; Satoko Toei-Shimizu; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

4.  Effect of neutralizing transforming growth factor beta1 on the immune response against Mycobacterium tuberculosis in guinea pigs.

Authors:  Shannon Sedberry Allen; Lynne Cassone; Todd M Lasco; David N McMurray
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

5.  Chitin-binding domains of Escherichia coli ChiA mediate interactions with intestinal epithelial cells in mice with colitis.

Authors:  Daren Low; Hoa T Tran; In-Ah Lee; Nicolas Dreux; Alan Kamba; Hans-Christian Reinecker; Arlette Darfeuille-Michaud; Nicolas Barnich; Emiko Mizoguchi
Journal:  Gastroenterology       Date:  2013-05-16       Impact factor: 22.682

6.  CHI3L1 (Chitinase 3 Like 1) upregulation is associated with macrophage signatures in esophageal cancer.

Authors:  Jing Huang; Zhenlin Gu; Yingying Xu; Lei Jiang; Weiguo Zhu; Wanwei Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 7.  Chitinase-3 like-protein-1 function and its role in diseases.

Authors:  Ting Zhao; Zhongping Su; Yingchang Li; Xiaoren Zhang; Qiang You
Journal:  Signal Transduct Target Ther       Date:  2020-09-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.